A message from the CEO:
Over the past few years, transcatheter aortic valve implantation (TAVI) has become an established therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. Several thousand patients have been effectively treated with minimally-invasive procedures and the majority has attained very favorable results.
Since the company’s founding, JenaValve™ Technology has endeavored to develop safe implantation systems for both the transapical, as well as the transfemoral approach. In collaborating with our scientific team, it has become clear that the correct and precise placement of a new prosthesis in the patient annulus is key to treatment safety and success, and ultimately, patient well-being. Not only are system design and features pivotal, but equally important are the dexterity, skill and experience of the user, whether heart surgeon or cardiologist.
To create a system that ensures precise placement, JenaValve has focused its product development on three fundamental, patented, design features: unique positioning feelers, the JenaClip™ and the low profile of the JenaValve prosthesis. These are the elemental differentiators with which the implantation can be accomplished more precisely and more easily than with other available TAVI systems.
Safety is our highest priority, for the patient as well as for the user. The JenaValve systems are designed so that physicians can become familiar with them quickly and can implant the aortic valve prosthesis safely.
In the years ahead, TAVI will become the treatment of preference for a growing world market. However, to treat other patients with this innovative method – in addition to high-risk cases – positive long-term evidence is needed to confirm the durability of the heart valve prosthesis. JenaValve has chosen the finest valve material available for its prosthesis and will employ biological valves for both systems. In fact, the transapical system features a valve that has many years of proven durability in clinical application.
Quality is of overriding importance to us, the mainstay of every aspect of our technology development, design process and product engineering, reflecting our outstanding German tradition. We look forward to producing the highest quality TAVI systems in the service of medical science and contributing life-enhancing products for patients worldwide.
JenaClip is a trademark of JenaValve™ Technology GmbH
|
|
Helmut J. Straubinger
President and CEO,
JenaValve Technology
 Download the new 2010 Company profile
|
© JenaValve™ Technology 2010. Do not reproduce without permission.
Print Page
Send Page
Information
